Osimertinib

MADRID — The combination of amivantamab and lazertinib improved PFS compared with osimertinib as first-line treatment for EGFR-mutated advanced non-small cell lung cancer, according to study results presented at ESMO Congress.

Healio spoke with Melina Elpi Marmarelis, MD, about data from the INSIGHT 2 trial presented at this year’s International Association for the Study of Lung Cancer World Conference on Lung Cancer.

Melina Elpi Marmarelis, MD, discussed research on the use of osimertinib versus durvalumab following chemoradiation in patients with stage III EGFR-mutated NSCLC.

Osimertinib plus chemotherapy may benefit some lung cancer subsets compared with osimertinib alone, according to recent research from the FLAURA2 trial.

Amivantamab plus lazertinib improved PFS compared with osimertinib as first-line therapy in adults with locally advanced or metastatic EGFR-mutated non-small cell lung cancer, according to the agent’s manufacturer.

Osimertinib plus chemotherapy conferred significantly greater improvement in PFS compared with osimertinib alone in patients with EGFR-mutated advanced non-small cell lung cancer, according to study results.

Amivantamab-vmjw — with or without the addition of lazertinib — improved PFS versus chemotherapy alone in patients with EGFR-mutated non-small cell lung cancer, according to the agent’s manufacturer.

Today is World Lung Cancer Day.

Healio spoke with Howard (Jack) West, MD, associate clinical professor of medical oncology at City of Hope Comprehensive Cancer Center, about results from the ADAURA trial presented at ASCO Annual Meeting.

In this interview, Charu Aggarwal, MD, MPH, discusses results from ADAURA trial presented at this year’s ASCO Annual Meeting.